Cite
MLA Citation
E. Van Cutsem et al.. “2108 Subgroup analysis by KRAS status in RAISE: A randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression during or following first-line combination therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine.” European journal of cancer, vol. 51, n.d., pp. S365–. http://access.bl.uk/ark:/81055/vdc_100030628213.0x000061